About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Use of Botulinum Toxin to Treat Psoriasis | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT00816517

Use of Botulinum Toxin to Treat Psoriasis

Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoria...

Lead sponsor: University of Minnesota•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Minnesota

Collaborators

Allergan

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Healthy subjects. Psoriasis vulgaris diagnosis made by a board certified dermatologist involving at least one area that has been intolerant or recalcitrant to at least two forms of recognized topical or systemic treatments in the past. In addition, the subject should have at least a score of 2 for keratoderma and erythema. Signed informed consent. Willing to adhere to protocol.

Exclusion Criteria

•Immunosuppressed patients, pregnant, secondary skin infections, phototherapy within 4 weeks of the botulinum toxin injection, exposure to any topical or systemic retinoid treatment with the last 12 months, volunteers taking chloroquine and hydroxychloroquine, volunteers on warfarin.

Related studies

RECRUITINGPhase 4

Proactive TDM Versus Standard Use of Biologics in Psoriasis

NCT06398106 · Psoriasis Vulgaris

Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris

NCT07320872 · Psoriasis Vulgaris

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

NCT04080635 · Psoriasis Vulgaris

COMPLETEDPhase 4

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

NCT04306315 · Psoriasis Vulgaris

COMPLETEDPhase 4

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

NCT04340076 · Psoriasis, Psoriasis Vulgaris

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 4, 2016Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment8

Start dateJan 2009

Last updatedApr 4, 2016

Condition

Psoriasis Vulgaris

Locations shown

Univerisity of Minnesota

Minneapolis, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 4, 2016Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions